中梁控股(02772.HK)擬現金要約購買最多為最高接納金額髮行在外2021年到期優先票據
格隆匯 5 月 10日丨中梁控股(02772.HK)發佈公吿,公司正提出要約,按2021年票據每1,000美元本金額1,005美元的購買價以現金購買最多為最高接納金額的發行在外2021年票據。公司已於今日向合資格持有人提出要約購買,當中載列(其中包括)要約的條款、新發行條件及其他條件。
要約為公司積極管理其資產負債表負債及優化其債務架構政策的一部分。瑞士銀行香港分行、香港上海匯豐銀行有限公司及國泰君安證券(香港)有限公司擔任要約的交易商管理人,而D.F.King則擔任要約的資訊及交付代理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.